-
x
x
bid
ask
01:04 PM
Bearish
27
Bullish
48
sentiment
day range
52 week range
Prev Close
Open
Low
High
Volume0.00
Avg. Volume0.00
Market Cap0.00
Inst. Own
Beta
Short Ratio
Div & Yield /
EPS
P/E
1yr Target
50day MA
200day MA
CNQ.TO
Canadian Natural Resources Limited
106.52
04:00 PM
+
0.84
0.79%
G.TO
Augusta Gold Corp.
0.96
03:59 PM
-
0.07
6.80%
AAA.AX
BetaShares Australian High Interest Cash ETF
50.25
02:10 AM
+
0.01
0.02%
ACC.NS
ACC Limited
2533.05
05:59 AM
-
46.55
1.80%
600690.SS
Haier Smart Home Co., Ltd.
28.35
03:00 AM
-
0.08
0.28%
0700.HK
Tencent Holdings Limited
348.40
04:08 AM
+
9.00
2.65%
1101.TW
Taiwan Cement Corp.
31.80
01:30 AM
-
0.20
0.62%
20MICRONS.NS
20 Microns Limited
162.85
05:59 AM
+
5.90
3.76%
Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
News
...
7 Stocks to Sell as Banks Melt Down | investorplace.com • |
Nabriva (NBRV) Posts Positive Data From Cystic Fibrosis Study | zacks.com • |
Nabriva's stock is up after sharing antibiotic news | marketwatch.com • |
Nabriva Therapeutics plc (NBRV) Q3 2022 Earnings Call Transcript | seekingalpha.com • |
Nabriva Therapeutics to Report Third Quarter 2022 Financial Results and Recent Corporate Highlights on November 10, 2022 | globenewswire.com • |
What Is Going on With Nabriva Therapeutics (NBRV) Stock Today? | investorplace.com • |
Profile
...
Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2023-08-02 | 2023-06 | 0 | N/A | N/A | N/A |
2023-05-22 | 2023-03 | 0 | N/A | N/A | N/A |
2023-04-17 | 2022-12 | 0 | N/A | N/A | N/A |
2022-11-10 | 2022-09 | -4.03 | N/A | N/A | N/A |
2022-08-03 | 2022-06 | -5 | N/A | N/A | N/A |
2022-05-05 | 2022-03 | -4.75 | N/A | N/A | N/A |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2020-12-07 | Morgan Stanley | Upgrade | Equal-Weight | |
2020-04-09 | H.C. Wainwright | Downgrade | Buy | Neutral |
2020-04-09 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
2020-04-08 | Needham | Downgrade | Buy | Hold |
2020-03-19 | Wedbush | Downgrade | Outperform | Neutral |
2020-03-17 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2022-08-01 | BROOM COLIN | Director | 36.52K | Sale |
2022-08-01 | BURGESS DANIEL D | Director | 10.38K | Sale |
2022-08-01 | CORRIGAN MARK | Director | 7.20K | Sale |
2022-08-10 | DOLAN DANIEL | Chief Financial Officer | 0.00 | Conversion of Exercise of derivative security |
2022-08-10 | GELONE STEVEN P | President | 0.00 | Conversion of Exercise of derivative security |
2022-08-10 | GUICO-PABIA CHRISTINE J | Officer | 0.00 | Conversion of Exercise of derivative security |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-03-30 | Values First Advisors, Inc. | 26.68K | 41.36K | 0.83% |
2023-03-30 | Renaissance Technologies, LLC | 23.36K | 36.21K | 0.73% |
2023-03-30 | Frazier Life Sciences Management, L.P. | 17.02K | 26.39K | 0.53% |
2023-03-30 | Citadel Advisors Llc | 11.61K | 17.99K | 0.36% |
2023-03-30 | Morgan Stanley | 4.11K | 6.37K | 0.13% |
2023-03-30 | Advisor Group Holdings, Inc. | 2.01K | 3.11K | 0.06% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-02-27 | Fidelity NASDAQ Composite Index Fund | 1.71K | 2.65K | 0.05% |
Split
...
Split | Date |
---|---|
1 : 25 | 2022-09-16 |
1 : 10 | 2020-12-03 |
10 : 1 | 2017-06-26 |
This topic has been deleted. Only users with topic management privileges can see it.
-
Can’t wait for that stop loss raids tomorrow ...
-
-
Just keep loading
-
Waiting game. When it rips. You’ll have to hold your pants
-
-
-
-
Sell your 100k dude I wanna see 1.70 come on...
-
Great 5 day setup above the sma
-
Good stock if I were a day trader. Up and down. Current holder waiting for lift off
-
-
Load up now
-
Look at the strong buy now
-
This is always were support is 1.77. Time for a climb again.
-
-
-
-
SMH what in the world
-
Time for another NIKE swoosh
-
Thank you for 1.99
-
7 Stocks to Sell as Banks Melt Down
investorplace.com • -
Nabriva's stock is up after sharing antibiotic news
marketwatch.com • -
Nabriva Therapeutics plc (NBRV) Q3 2022 Earnings Call Transcript
seekingalpha.com • -
What Is Going on With Nabriva Therapeutics (NBRV) Stock Today?
investorplace.com • -
Buying Penny Stocks Today? What You Need to Know
pennystocks.com • -
Nabriva Therapeutics Announces Date of 1-for-25 Reverse Stock Split
globenewswire.com • -
Nabriva Therapeutics to Present at the Jefferies London Healthcare Conference
globenewswire.com • -
Nabriva Therapeutics to Present Data at CHEST Annual Meeting 2021
globenewswire.com • -
Nabriva Therapeutics to Present Data at IDWeek 2021
globenewswire.com • -
Nabriva Therapeutics, Vizient Inks Xenleta Distribution Pact
benzinga.com • -
NBRV Stock: Why It Increased Today
pulse2.com • -
Nabriva Announces Changes to its Board of Directors
globenewswire.com • -
Why Nabriva Therapeutics Stock Is Surging Today
benzinga.com • -
Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference
globenewswire.com • -
Nabriva Therapeutics Announces Retirement of its Chief Financial Officer
globenewswire.com • -
Nabriva Therapeutics Announces Pricing of $15 Million Public Offering
globenewswire.com • -
Nabriva Therapeutics Announces Proposed Public Offering
globenewswire.com • -
Nabriva (NBRV) to Report Q2 Earnings: What's in the Cards?
finance.yahoo.com • -
Lefamulin Demonstrates Anti-Inflammatory Activity in Pre-Clinical Study
finance.yahoo.com • -
Analyst Sees 60% Upside for Nabriva (NBRV) Following Merck Deal
finance.yahoo.com • -
Nabriva Soars on Agreement With Merck to Distribute Sivextro
finance.yahoo.com • -
CONTEPO CRL Is a Blow for Cash-Strapped Nabriva (NBRV), Says Analyst
finance.yahoo.com • -
CymaBay Seladelpar Data, And Other News: The Good, Bad And Ugly Of Biopharma
seekingalpha.com • -
Is Nabriva Therapeutics plc (NBRV) A Good Stock To Buy?
finance.yahoo.com • -
Nabriva Therapeutics (NBRV) Catches Eye: Stock Jumps 11.4%
finance.yahoo.com • -
Nabriva's Shares March Higher, Can It Continue?
finance.yahoo.com • -
Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates
finance.yahoo.com • -
Implied Volatility Surging for Nabriva (NBRV) Stock Options
finance.yahoo.com • -
Nabriva Therapeutics to Present at the Jefferies Virtual Healthcare Conference
finance.yahoo.com • -
Why Earnings Season Could Be Great for Nabriva Therapeutics (NBRV)
finance.yahoo.com •